William Blair Comments on Zevra Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at William Blair lifted their Q1 2024 earnings estimates for shares of Zevra Therapeutics in a research report issued on Tuesday, April 16th. William Blair analyst T. Lugo now anticipates that the company will post earnings of ($0.51) per share for the quarter, up from their previous estimate of ($0.52). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.65) per share. William Blair also issued estimates for Zevra Therapeutics’ Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.73) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.77) EPS.

Other equities research analysts also recently issued research reports about the stock. Maxim Group boosted their price objective on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research report on Monday, April 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, April 3rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $19.50.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $4.50 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.08. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $7.28. The firm has a 50-day simple moving average of $5.89 and a 200 day simple moving average of $5.36. The company has a market cap of $195.44 million, a PE ratio of -3.49 and a beta of 1.81.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter worth approximately $7,772,000. Janney Montgomery Scott LLC acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter worth approximately $3,250,000. Retirement Planning Co of New England Inc. acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter worth approximately $1,674,000. Northern Trust Corp acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter worth approximately $1,304,000. Finally, Armistice Capital LLC acquired a new stake in shares of Zevra Therapeutics in the 4th quarter worth approximately $1,755,000. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.